Lion Biotechnologies announces publication of data from clinical study of metastatic cervical cancer patients treated with HPV-TIL

Lion Biotechnologies, a biotechnology company that is developing novel cancer immunotherapies based on tumour-infiltrating lymphocytes (TIL), has announced that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) has been published.

Data from the trial showed objective responses, including durable, complete regressions, in patients after a single infusion of human papillomavirus tumour-infiltrating lymphocytes (HPV-TIL).

The trial was designed to determine if the infusion of human papillomavirus tumour-infiltrating lymphocytes could induce regression of advanced HPV-positive cancers. Of the nine metastatic cervical cancer patients who were enrolled and treated with HPV-TIL, three patients experienced objective tumour responses, two of whom experienced complete, ongoing remissions of 22 and 15 months, respectively. The other patient demonstrated a partial response of three months.

HPV-TIL treatment demonstrated potential efficacy

“We are pleased to see the results of this trial, which demonstrate potential efficacy of TIL treatment in metastatic cervical cancer, a notoriously difficult-to-treat cancer in women,” said Elma Hawkins, PhD, Lion’s president and chief executive officer. “We recently amended our CRADA with the NCI to include technologies based on the HPV-TIL research. With these technologies, we look forward to expanding our clinical programs and developing new treatment options for patients with cervical cancer and other solid tumours.”

Data from the study is published in Journal of Clinical Oncology in an article titled “Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells”.

For more information about Lion Biotechnologies, please visit www.lionbio.com.